CALGARY, July 25, 2017 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) announced today that it filed its audited Consolidated Financial Statements for the
year ended April 30, 2017 and related Management's Discussion and Analysis with Canadian securities
regulatory authorities. The Company has also filed its Annual Information Form for the year ended April
30, 2017. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing ir@resverlogix.com. An additional corporate financial update will take place prior to August 28 th, 2017.
Resverlogix to Host Symposium at the European Society of Cardiology Congress 2017
The Company also announced today that on Saturday, August 26, 2017, at the European Society of
Cardiology (ESC) Congress in Barcelona, Spain, it will host a symposium titled: "Managing
Diabetes & CVD: Is epigenetics a new way forward?"
The agenda and speakers are as follows:
Introduction
Lina Badimon, MD – Barcelona, Spain
Managing high risk diabetes patients with cardiovascular disease: What works, and what else can we do? -
Kausik Ray, MD - Imperial College London, United
Kingdom
Promise of epigenetic modulation as a target in atherosclerotic patients
- Erik Stroes, MD - Academic Medical Centre, Amsterdam,
Netherlands
Insights from the first trials in epigenetics in human: What is the way forward?
- Stephen Nicholls, MD - Adelaide,
Australia
Presentations will be made available at: www.pace-cme.org.
Mr. Donald McCaffrey, President and CEO commented, "The presentations at the ESC Congress
symposium will highlight apabetalone and its opportunity as a novel approach to the treatment of high-risk cardiovascular disease
in patients with diabetes. Data to be presented demonstrates the important role for epigenetics in the underlying pathology of
these diseases." Mr. McCaffrey added, "Importantly, we remain encouraged by the recent data safety monitoring board review and
recommendation to once again continue with the Phase 3 BETonMACE trial as planned. The trial has already enrolled over 70 percent
of the planned 2,400 patients and remains on track with internal projections."
Resverlogix will also present two posters at the congress titled:
i)
|
"Lowering the neutrophil to lymphocyte ratio by the BET inhibitor,
apabetalone: potential implications for cardiovascular events in high risk patients"
|
|
|
|
Poster Presentation Details:
|
|
|
|
Date: Sunday, August 27, 2017
|
|
Time: 9:30am – 10:45am CET
|
|
Session number: 302
|
|
Session title: Poster Session 2
|
|
|
ii)
|
"Apabetalone (RVX-208) impacts key biomarkers and pathways associated with
cardiovascular disease in patients with severe renal impairment"
|
|
|
|
Poster Presentation Details:
|
|
|
|
Date: Tuesday, August 29, 2017
|
|
Time: 3:30pm – 4:30pm CET
|
|
Session number: 307
|
|
Session title: Poster Session 7
|
The posters will be made available HERE on the Company's website
at the time of their respective presentation dates and times at the congress.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and
extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4.
This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits
for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease
treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while
maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical
trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low
high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate
biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone
in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative
disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be
materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of
the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this
cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE Resverlogix Corp.
View original content: http://www.newswire.ca/en/releases/archive/July2017/25/c6402.html